NCT00897390View on ClinicalTrials.gov

Bioequivalence Study of Saxagliptin and Glucophage Combination Formulations in Healthy Subjects (B)

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

June 30, 2009

Primary Completion Date

July 31, 2009

Study Completion Date

July 31, 2009

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

Saxagliptin

Tablet, Oral, 2.5 mg, Once Daily, 1 week

DRUG

Metformin IR (glucophage)

Tablets, Oral, 1000 mg, Once Daily, 1 week

DRUG

Saxagliptin + Metformin IR (FDC)

Tablet, Oral, Saxagliptin 2.5 mg + metformin IR 1000 mg, Once Daily, 1 Week

Trial Locations (1)

68502

Mds Pharma Services, Lincoln

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY